PCRX Pacira BioSciences, Inc. Stock Quote

PCRX [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	74.87	EPS (ttm)	0.84	Insider Own	1.00%	Shs Outstand	44.87M	Perf Week	3.11%
Market Cap	2.84B	Forward P/E	14.12	EPS next Y	4.47	Insider Trans	-24.51%	Shs Float	44.15M	Perf Month	-16.21%
Income	38.40M	PEG	2.67	EPS next Q	0.86	Inst Own	-	Short Float	12.10%	Perf Quarter	-1.58%
Sales	580.50M	P/S	4.90	EPS this Y	-72.40%	Inst Trans	1.88%	Short Ratio	9.33	Perf Half Y	11.03%
Book/sh	15.81	P/B	3.99	EPS next Y	30.55%	ROA	2.30%	Target Price	80.46	Perf Year	-4.93%
Cash/sh	10.02	P/C	6.29	EPS next 5Y	28.00%	ROE	5.40%	52W Range	45.05 - 82.16	Perf YTD	4.77%
Dividend	-	P/FCF	27.38	EPS past 5Y	23.80%	ROI	4.20%	52W High	-23.27%	Beta	0.94
Dividend %	-	Quick Ratio	1.80	Sales past 5Y	14.40%	Gross Margin	75.00%	52W Low	39.93%	ATR	3.08
Employees	697	Current Ratio	2.20	Sales Q/Q	32.80%	Oper. Margin	15.10%	RSI (14)	38.94	Volatility	4.07% 4.56%
Optionable	Yes	Debt/Eq	1.30	EPS Q/Q	-33.50%	Profit Margin	6.60%	Rel Volume	0.90	Prev Close	61.41
Shortable	Yes	LT Debt/Eq	1.03	Earnings	May 04 BMO	Payout	0.00%	Avg Volume	572.52K	Price	63.04
Recom	2.00	SMA20	-7.25%	SMA50	-12.55%	SMA200	1.91%	Volume	514,722	Change	2.65%

Jan-03-22

Resumed

JP Morgan

Overweight

$75 → $83

Jul-26-21

Upgrade

JP Morgan

Neutral → Overweight

$75

Apr-21-21

Resumed

JP Morgan

Neutral

$70

Apr-09-21

Initiated

Berenberg

Buy

$93

Apr-07-21

Resumed

RBC Capital Mkts

Outperform

$86

Feb-11-21

Downgrade

Northland Capital

Outperform → Market Perform

$72 → $75

Jan-21-21

Downgrade

SVB Leerink

Outperform → Mkt Perform

$75

Sep-21-20

Upgrade

Northland Capital

Market Perform → Outperform

$58 → $67

Jul-06-20

Reiterated

Needham

Buy

$52 → $64

May-27-20

Initiated

Guggenheim

Neutral

Apr-07-20

Initiated

Northland Capital

Outperform

$50

Mar-20-20

Upgrade

SVB Leerink

Mkt Perform → Outperform

$44

Feb-24-20

Reiterated

H.C. Wainwright

Buy

$60 → $63

Jan-24-20

Initiated

SunTrust

Buy

Jan-23-20

Initiated

SunTrust

Buy

Nov-06-19

Initiated

BTIG Research

Buy

$56

Jun-11-19

Initiated

Barclays

Overweight

$52

May-06-19

Upgrade

Mizuho

Underperform → Neutral

$29 → $38

May-02-19

Upgrade

Stifel

Sell → Hold

$45

Feb-01-19

Downgrade

Mizuho

Neutral → Underperform

May-12-22 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $45.8 Million for April 2022 GlobeNewswire
May-10-22 09:45AM	Here's Why Pacira (PCRX) is a Strong Growth Stock Zacks
08:00AM	Pacira BioSciences to Present at Two Healthcare Conferences in May GlobeNewswire
May-05-22 11:26AM	Pacira's (PCRX) Q1 Earnings Miss Estimates, Revenues Rise Y/Y Zacks -6.75%
May-04-22 09:15AM	Pacira (PCRX) Q1 Earnings Miss Estimates Zacks -6.10%
08:00AM	Pacira BioSciences Reports First Quarter 2022 Financial Results GlobeNewswire
Apr-28-22 12:10PM	Why Pacira (PCRX) Could Beat Earnings Estimates Again Zacks
Apr-27-22 11:15AM	3 Small-Cap Medical Stocks With Big Momentum Motley Fool
08:00AM	Pacira to Report First Quarter 2022 Financial Results on Wednesday May 4, 2022 GlobeNewswire
Apr-26-22 03:01PM	Pacira (PCRX) to Report Q1 Results: Wall Street Expects Earnings Growth Zacks
Apr-19-22 09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick Zacks
Apr-13-22 05:24PM	Billionaire John Paulsons Latest Portfolio: Top 10 Stock Picks Insider Monkey
Apr-12-22 08:00AM	Pacira BioSciences Reports Preliminary Revenues of $157.4 to $158.4 Million for the First Quarter of 2022 GlobeNewswire
Apr-05-22 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-23-22 09:27AM	3 High-Growth Stocks Hitting Fresh 52-Week Highs TipRanks
Mar-15-22 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $42.6 Million for February 2022 GlobeNewswire
Mar-09-22 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the Barclays Global Healthcare Conference GlobeNewswire
Mar-08-22 08:56AM	Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Popularity With Investors Is Clear Simply Wall St.
Mar-07-22 10:23AM	Pacira (PCRX) Rides High in YTD Period on Robust Exparel Sales Zacks
Feb-25-22 11:09AM	Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y Zacks
Feb-24-22 09:25AM	Pacira (PCRX) Q4 Earnings and Revenues Beat Estimates Zacks
08:00AM	Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results GlobeNewswire
Feb-17-22 03:02PM	Earnings Preview: Pacira (PCRX) Q4 Earnings Expected to Decline Zacks
Feb-16-22 08:00AM	Pacira to Report 2021 Financial Results on Thursday February 24, 2022 GlobeNewswire
Feb-15-22 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $37.3 Million for January 2022 GlobeNewswire
Feb-07-22 08:38PM	Hodges Capital Management Inc. Buys On Holding AG, Wells Fargo, Chesapeake Energy Corp, Sells ... GuruFocus.com
01:39PM	Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating Investor's Business Daily
Feb-04-22 12:10PM	Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report? Zacks
09:38AM	Lisanti Capital Growth, LLC Buys Saia Inc, Knight-Swift Transportation Holdings Inc, ... GuruFocus.com
Feb-02-22 09:38PM	Barnett & Company, Inc. Buys iShares Russell 1000 Growth ETF, iShares Russell 1000 Value ... GuruFocus.com
09:38AM	Mount Yale Investment Advisors, LLC Buys Discover Financial Services, Phillips 66, BTC iShares ... GuruFocus.com
09:38AM	Demars Financial Group, LLC Buys iShares TIPS Bond ETF, Medical Properties Trust Inc, Phillips ... GuruFocus.com
Feb-01-22 05:38PM	Polaris Capital Management, LLC Buys FedEx Corp, Allison Transmission Holdings Inc, Wabash ... GuruFocus.com
Jan-06-22 08:00AM	Pacira Reports Preliminary Unaudited Total Revenue for 2021 of $540.7 Million to $541.7 Million GlobeNewswire
Jan-04-22 12:45PM	Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why Zacks
Jan-03-22 08:00AM	Pacira BioSciences to Present at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-15-21 12:38AM	Tributary Small Company Fund Buys Cambium Networks Corp, Sunstone Hotel Investors Inc, Integer ... GuruFocus.com
12:38AM	Tributary Funds, Inc. Buys Cambium Networks Corp, Pacira BioSciences Inc, LHC Group Inc, Sells ... GuruFocus.com
Dec-11-21 01:05PM	Hedge Funds Are Crazy About Pacira Biosciences Inc (PCRX) Insider Monkey
Dec-09-21 08:00AM	Pacira BioSciences Announces Closing of $375 Million Five-Year Term Loan B GlobeNewswire
Dec-07-21 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL® and iovera° of $48.0 Million for November 2021 GlobeNewswire
Dec-06-21 11:32AM	15 Best Stocks to Buy for 2022 According to Analysts Insider Monkey
Dec-03-21 11:31AM	Pacira (PCRX) Down 4.5% Since Last Earnings Report: Can It Rebound? Zacks
Nov-23-21 08:00AM	Pacira BioSciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference GlobeNewswire
Nov-19-21 08:40AM	Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management GlobeNewswire
Nov-18-21 10:00AM	Those who invested in Pacira BioSciences (NASDAQ:PCRX) five years ago are up 75% Simply Wall St.
Nov-10-21 08:00AM	Pacira BioSciences to Present at the Jefferies London Healthcare Conference GlobeNewswire
Nov-09-21 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $44.3 Million for October 2021 GlobeNewswire
Nov-08-21 04:30PM	Pacira Files Lawsuit Against eVenus for Patent Infringement GlobeNewswire
Nov-03-21 01:30PM	Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark Zacks +5.15%
01:01PM	Pacira BioSciences, inc (PCRX) Q3 2021 Earnings Call Transcript Motley Fool
09:15AM	Pacira (PCRX) Beats Q3 Earnings Estimates Zacks
08:00AM	Pacira BioSciences Reports Third Quarter 2021 Financial Results GlobeNewswire
Nov-02-21 06:35PM	FLEXION THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion Therapeutics, Inc. - FLXN PR Newswire
07:30AM	Pacira Receives Notice of Allowance for New Patent Covering EXPAREL Composition GlobeNewswire
Oct-27-21 07:30AM	Pacira to Report Third Quarter 2021 Financial Results on Wednesday November 3, 2021 GlobeNewswire
Oct-26-21 09:34AM	Hedge Funds Are Coming Back To Pacira Biosciences Inc (PCRX) Insider Monkey
Oct-21-21 05:25PM	Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Meredith Corporation, Aspen Technology, Flexion, and Columbia Banking System on behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
Oct-13-21 07:17PM	SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Flexion Therapeutics, Inc. (Nasdaq - FLXN) ACCESSWIRE
12:40PM	FLEXION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of FLXN and Encourages Investors to Contact the Firm GlobeNewswire
Oct-12-21 12:00PM	SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Flexion Therapeutics, Inc. Merger GlobeNewswire
Oct-11-21 11:41PM	SHAREHOLDER ALERT: WeissLaw LLP Investigates Flexion Therapeutics, Inc. PR Newswire +5.82%
04:26PM	ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Flexion Therapeutics, Inc. PR Newswire
08:07AM	(FLXN): Johnson Fistel Investigates Proposed Sale of Flexion; Are Shareholders Getting a Fair Deal? GlobeNewswire
07:52AM	Pacira BioSciences Nears $630 Million Deal for Flexion Bloomberg
07:00AM	Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management GlobeNewswire
Oct-08-21 08:00AM	Pacira BioSciences to Host Investor Day on October 15th, 2021 in Tampa, FL GlobeNewswire
Oct-05-21 08:57AM	Pacira (PCRX) Gets Notification of ANDA for Exparel, Stock Down Zacks
Oct-04-21 03:56PM	Why Pacira Biosciences Stock Sank Today Motley Fool -13.22%
01:26PM	These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely Simply Wall St.
07:30AM	Pacira BioSciences Notified of Abbreviated New Drug Application Filing for EXPAREL® GlobeNewswire
Sep-30-21 07:30AM	Pacira Announces Commercial Production Underway with Enhanced EXPAREL Manufacturing Process at Swindon Facility GlobeNewswire
Sep-21-21 07:30AM	Pacira Announces Publication of Phase 3 Study of EXPAREL Infiltration in Pediatric Patients Undergoing Spinal or Cardiac Surgeries GlobeNewswire
Sep-15-21 07:30AM	Pacira BioSciences Reports Preliminary Net Product Sales of $42.3 Million for August 2021 GlobeNewswire
Sep-08-21 08:00AM	Pacira BioSciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Sep-02-21 11:31AM	Pacira (PCRX) Down 1.6% Since Last Earnings Report: Can It Rebound? Zacks
Aug-10-21 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $42.1 Million for July 2021 GlobeNewswire -7.23%
Aug-05-21 06:50AM	Will Weakness in Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Prove Temporary Given Strong Fundamentals? Simply Wall St.
Aug-04-21 10:38AM	Pacira's (PCRX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y Zacks
Aug-03-21 06:30PM	Pacira BioSciences, inc (PCRX) Q2 2021 Earnings Call Transcript Motley Fool
09:15AM	Pacira (PCRX) Q2 Earnings Surpass Estimates Zacks
08:00AM	Pacira BioSciences Reports Record Revenue of $135.6 Million for the Second Quarter of 2021 GlobeNewswire
Aug-02-21 10:26AM	10 Best Stocks to Buy According to John Paulson Insider Monkey
08:00AM	Pacira Announces FDA Approval of Enhanced EXPAREL Manufacturing Process GlobeNewswire
Jul-29-21 07:30AM	New Analysis Shows iovera° Plays a Critical Role in Achieving Significant Reductions in Opioid Use, Pain Scores, and Hospital Stay Following Total Knee Arthroplasty GlobeNewswire
Jul-27-21 03:03PM	Pacira (PCRX) Earnings Expected to Grow: Should You Buy? Zacks
Jul-21-21 10:14AM	Hedge Fund Sentiment Is Stagnant On Pacira Biosciences Inc (PCRX) Insider Monkey
Jul-20-21 07:30AM	Pacira to Report Second Quarter 2021 Financial Results on Tuesday August 3, 2021 GlobeNewswire
Jul-13-21 08:00AM	Pacira BioSciences Reports Record Revenue of $135.6 Million for the Second Quarter of 2021 GlobeNewswire
Jun-22-21 08:00AM	Pacira Announces EXPAREL Distribution Agreement with Eurofarma in Latin America GlobeNewswire
Jun-08-21 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $42.2 Million for May 2021 GlobeNewswire
Jun-03-21 11:31AM	How Has PCRX Performed 30 Days Post Earnings Zacks
May-26-21 09:23AM	Pacira BioSciences' Exparel Misses Primary Endpoint In Post-Op Pain Study After Lower Extremity Surgeries Benzinga
08:00AM	Pacira BioSciences Announces Top-line Results from Phase 3 STRIDE Study Evaluating EXPAREL as a Lower Extremity Nerve Block GlobeNewswire
May-25-21 08:00AM	Pacira BioSciences to Present at the 2021 Jefferies Virtual Healthcare Conference GlobeNewswire
May-18-21 08:00AM	Pacira BioSciences Announces Notice of Allowance of New Patent for EXPAREL GlobeNewswire
May-12-21 08:00AM	Pacira BioSciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference GlobeNewswire
May-11-21 08:00AM	Pacira BioSciences Reports Preliminary Net Product Sales of $44.6 Million for April 2021 GlobeNewswire
May-05-21 08:11AM	Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat Zacks
May-04-21 02:30PM	Pacira BioSciences, Inc. (PCRX) Q1 2021 Earnings Call Transcript Motley Fool

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Parsippany, New Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Froimson Mark	Director	May 09	Sale	59.37	1,000	59,370	4,908	May 11 04:13 PM
STACK DAVID M	CEO and Chairman	Apr 28	Option Exercise	10.81	22,500	243,225	168,044	May 02 06:34 PM
REINHARDT MAX	President, Rest of World	Apr 21	Option Exercise	42.54	12,500	531,750	39,474	Apr 25 04:12 PM
REINHARDT MAX	President, Rest of World	Apr 21	Sale	73.25	9,824	719,647	29,650	Apr 25 04:12 PM
REINHARDT MAX	President, Rest of World	Apr 20	Option Exercise	42.54	12,500	531,750	36,738	Apr 20 08:25 PM
REINHARDT MAX	President, Rest of World	Apr 20	Sale	73.99	9,764	722,438	26,974	Apr 20 08:25 PM
REINHARDT MAX	President, Rest of World	Apr 19	Option Exercise	42.54	12,500	531,750	33,559	Apr 20 08:25 PM
REINHARDT MAX	President, Rest of World	Apr 19	Sale	72.25	9,321	673,442	24,238	Apr 20 08:25 PM
REINHARDT MAX	President, Rest of World	Apr 18	Option Exercise	42.54	12,500	531,750	30,000	Apr 20 08:25 PM
REINHARDT MAX	President, Rest of World	Apr 18	Sale	73.55	8,941	657,611	21,059	Apr 20 08:25 PM
MOLLOY ANTHONY	Chief Lgl & Compliance Officer	Apr 06	Option Exercise	40.77	22,500	917,407	40,050	Apr 08 04:16 PM
MOLLOY ANTHONY	Chief Lgl & Compliance Officer	Apr 06	Sale	76.42	22,500	1,719,393	17,550	Apr 08 04:16 PM
STACK DAVID M	CEO and Chairman	Mar 31	Option Exercise	10.81	22,500	243,225	145,544	Apr 05 05:26 PM
Williams Kristen Marie	Chief Administrative Officer	Mar 21	Option Exercise	42.67	7,253	309,462	29,521	Mar 23 04:37 PM
Williams Kristen Marie	Chief Administrative Officer	Mar 21	Sale	72.67	7,253	527,076	22,268	Mar 23 04:37 PM
Riker Lauren Bullaro	Senior Vice President, Finance	Mar 10	Option Exercise	10.81	9,300	100,533	24,452	Mar 14 05:00 PM
Riker Lauren Bullaro	Senior Vice President, Finance	Mar 10	Sale	71.22	9,300	662,331	15,152	Mar 14 05:00 PM
LONGENECKER JOHN P PHD	Director	Mar 03	Option Exercise	10.81	7,000	75,670	25,823	Mar 07 08:03 PM
PACE GARY W	Director	Mar 03	Option Exercise	10.81	7,000	75,670	136,530	Mar 07 08:07 PM
LONGENECKER JOHN P PHD	Director	Mar 03	Sale	71.73	7,000	502,145	18,823	Mar 07 08:03 PM
PACE GARY W	Director	Mar 01	Option Exercise	11.02	1,359	14,976	130,889	Mar 01 06:03 PM
PACE GARY W	Director	Mar 01	Sale	67.75	1,359	92,072	129,530	Mar 01 06:03 PM
PACE GARY W	Director	Feb 28	Option Exercise	11.02	28,641	315,624	158,171	Mar 01 06:03 PM
PACE GARY W	Director	Feb 28	Sale	66.83	28,641	1,914,078	129,530	Mar 01 06:03 PM
Williams Kristen Marie	Chief Administrative Officer	Feb 25	Option Exercise	38.35	2,050	78,618	24,318	Mar 01 05:43 PM
Williams Kristen Marie	Chief Administrative Officer	Feb 25	Sale	67.02	2,050	137,390	22,268	Mar 01 05:43 PM
Williams Kristen Marie	Chief Administrative Officer	Feb 16	Option Exercise	38.35	10	384	22,278	Mar 01 05:43 PM
Williams Kristen Marie	Chief Administrative Officer	Feb 16	Sale	65.00	10	650	22,268	Mar 01 05:43 PM
Williams Kristen Marie	Chief Administrative Officer	Feb 04	Option Exercise	38.35	1,000	38,350	23,268	Feb 08 04:25 PM
Williams Kristen Marie	Chief Administrative Officer	Feb 04	Sale	65.18	1,000	65,180	22,268	Feb 08 04:25 PM
STACK DAVID M	CEO and Chairman	Jan 25	Option Exercise	10.81	13,670	147,773	123,044	Jan 27 04:27 PM
Williams Kristen Marie	Chief Administrative Officer	Jan 21	Option Exercise	38.35	200	7,670	22,468	Jan 25 04:36 PM
Williams Kristen Marie	Chief Administrative Officer	Jan 21	Sale	65.41	200	13,082	22,268	Jan 25 04:36 PM
Williams Kristen Marie	Chief Administrative Officer	Jan 19	Option Exercise	38.35	2,199	84,332	24,467	Jan 20 07:24 PM
Williams Kristen Marie	Chief Administrative Officer	Jan 19	Sale	65.51	2,199	144,056	22,268	Jan 20 07:24 PM
Riker Lauren Bullaro	Senior Vice President, Finance	Jan 18	Option Exercise	10.81	2,500	27,025	17,652	Jan 20 07:22 PM
Williams Kristen Marie	Chief Administrative Officer	Jan 18	Option Exercise	45.30	23,440	1,061,943	45,708	Jan 20 07:24 PM
Williams Kristen Marie	Chief Administrative Officer	Jan 18	Sale	65.26	23,440	1,529,586	22,268	Jan 20 07:24 PM
Riker Lauren Bullaro	Senior Vice President, Finance	Jan 18	Sale	64.97	2,500	162,430	15,152	Jan 20 07:22 PM
MOLLOY ANTHONY	Chief Lgl & Compliance Officer	Jan 18	Sale	63.55	224	14,235	17,550	Jan 20 07:21 PM
STACK DAVID M	CEO and Chairman	Jan 11	Option Exercise	10.81	15,000	162,150	109,374	Jan 13 04:11 PM
LARANJEIRA CHARLES ANTHONY	Chief Technical Officer	Nov 22	Option Exercise	44.10	7,500	330,750	33,602	Nov 24 04:25 PM
STACK DAVID M	CEO and Chairman	Nov 16	Option Exercise	10.81	15,000	162,150	94,085	Nov 18 04:22 PM
WINSTON ROY	Chief Medical Officer	Nov 04	Option Exercise	48.15	10,000	481,500	46,456	Nov 08 04:22 PM
Riker Lauren Bullaro	Vice President, Finance	Jul 29	Option Exercise	10.81	90	973	13,242	Jul 30 04:21 PM
Riker Lauren Bullaro	Vice President, Finance	Jul 29	Sale	60.81	90	5,473	13,152	Jul 30 04:21 PM
Riker Lauren Bullaro	Vice President, Finance	Jul 28	Option Exercise	10.81	2,410	26,052	15,562	Jul 30 04:21 PM
Riker Lauren Bullaro	Vice President, Finance	Jul 28	Sale	60.85	2,410	146,648	13,152	Jul 30 04:21 PM
REINHARDT MAX	President, Rest of World	Jul 02	Sale	59.76	421	25,159	17,500	Jul 06 06:14 PM
Riker Lauren Bullaro	Vice President, Finance	Jun 11	Sale	59.85	2,003	119,880	12,731	Jun 11 08:39 PM
Williams Kristen Marie	Chief Administrative Officer	Jun 10	Sale	59.60	5,689	339,063	22,268	Jun 11 08:38 PM
Manning Donald C.	Chief Medical Officer	Jun 08	Sale	61.14	2,600	158,964	23,520	Jun 10 06:07 PM
REINHARDT MAX	President, Rest of World	Jun 07	Sale	60.50	2,278	137,819	10,500	Jun 08 04:16 PM
Williams Kristen Marie	Chief Administrative Officer	Jun 04	Sale	61.04	3,930	239,875	20,957	Jun 08 04:20 PM
WINSTON ROY	Chief Clinical Officer	Jun 04	Sale	61.04	2,276	138,920	24,035	Jun 08 04:20 PM
STACK DAVID M	CEO and Chairman	Jun 04	Sale	61.04	14,905	909,756	61,156	Jun 08 04:18 PM
Reinhart Charles A. III	Chief Financial Officer	Jun 04	Sale	61.04	2,648	161,626	24,799	Jun 08 04:17 PM
Riker Lauren Bullaro	Vice President, Finance	Jun 04	Sale	61.04	1,047	63,906	12,134	Jun 08 04:17 PM
REINHARDT MAX	President, Rest of World	Jun 04	Sale	61.04	1,222	74,587	12,778	Jun 08 04:16 PM
McLoughlin Dennis	Chief Customer Officer	Jun 04	Sale	61.04	1,895	115,665	27,541	Jun 08 04:15 PM
LARANJEIRA CHARLES ANTHONY	Chief Technical Officer	Jun 04	Sale	61.04	2,117	129,215	18,681	Jun 08 04:14 PM
HASTINGS PAUL J	Director	Jun 04	Sale	62.19	630	39,180	5,486	Jun 08 04:13 PM
Manning Donald C.	Chief Medical Officer	Jun 02	Sale	62.12	2,380	147,853	26,120	Jun 04 05:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience